Skip to main content
NCBI home page
Biochemical Journal logoLink to Biochemical Journal
. 2002 Aug 15;366(Pt 1):273–279. doi: 10.1042/BJ20020207

Apolipoprotein E structural requirements for the formation of SDS-stable complexes with beta-amyloid-(1-40): the role of salt bridges.

Nicholas M Bentley 1, Mary Jo Ladu 1, Chandrika Rajan 1, Godfrey S Getz 1, Catherine A Reardon 1
PMCID: PMC1222763  PMID: 12015813

Abstract

Of the three major isoforms of human apolipoprotein E (apoE), apoE4 is a risk factor for the development of Alzheimer's disease. Among possible neurologically relevant differences in the properties of apoE3 and apoE4 is the fact that apoE3 forms an SDS-stable complex with beta-amyloid-(1-40) (Abeta40) with greater avidity than does apoE4. This interaction may sequester potentially toxic species of Abeta or facilitate clearance. To understand more about this difference, we examined whether differences in salt bridges between apoE domains influence the capacity of apoE isoforms to form complexes with Abeta. In apoE3 there is a salt bridge between Arg-61 and Asp-65, while in apoE4 there are salt bridges between Arg-61 and Glu-255, and Arg-112 and Glu-109. Mutation of position 112, which is Cys in apoE3 and Arg in apoE4, to Ala or Lys abolished complex formation, while mutant apoE with Ser at this position retained the capacity to form complex. Substituting Ala for Glu-109 had no effect on the ability of either apoE4 or apoE3 to form complexes. On the other hand, substitution of Thr for Arg-61 in apoE3 abolished, and truncation of apoE3 at position 201 substantially lowered, but did not abolish, complex formation. Neither of these mutations within apoE4 had any affect on its complex formation with Abeta. These results suggest that the nature of the cysteine residue in apoE3 and interactions between the N-terminal and C-terminal domains of human apoE are important for the ability of apoE3 to form an SDS-stable complex with Abeta40.

Full Text

The Full Text of this article is available as a PDF (201.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aggerbeck L. P., Wetterau J. R., Weisgraber K. H., Wu C. S., Lindgren F. T. Human apolipoprotein E3 in aqueous solution. II. Properties of the amino- and carboxyl-terminal domains. J Biol Chem. 1988 May 5;263(13):6249–6258. [PubMed] [Google Scholar]
  2. Aleshkov S., Abraham C. R., Zannis V. I. Interaction of nascent ApoE2, ApoE3, and ApoE4 isoforms expressed in mammalian cells with amyloid peptide beta (1-40). Relevance to Alzheimer's disease. Biochemistry. 1997 Aug 26;36(34):10571–10580. doi: 10.1021/bi9626362. [DOI] [PubMed] [Google Scholar]
  3. Bellosta S., Nathan B. P., Orth M., Dong L. M., Mahley R. W., Pitas R. E. Stable expression and secretion of apolipoproteins E3 and E4 in mouse neuroblastoma cells produces differential effects on neurite outgrowth. J Biol Chem. 1995 Nov 10;270(45):27063–27071. doi: 10.1074/jbc.270.45.27063. [DOI] [PubMed] [Google Scholar]
  4. Borchelt D. R., Ratovitski T., van Lare J., Lee M. K., Gonzales V., Jenkins N. A., Copeland N. G., Price D. L., Sisodia S. S. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron. 1997 Oct;19(4):939–945. doi: 10.1016/s0896-6273(00)80974-5. [DOI] [PubMed] [Google Scholar]
  5. Boyles J. K., Pitas R. E., Wilson E., Mahley R. W., Taylor J. M. Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J Clin Invest. 1985 Oct;76(4):1501–1513. doi: 10.1172/JCI112130. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Carter D. B., Dunn E., McKinley D. D., Stratman N. C., Boyle T. P., Kuiper S. L., Oostveen J. A., Weaver R. J., Boller J. A., Gurney M. E. Human apolipoprotein E4 accelerates beta-amyloid deposition in APPsw transgenic mouse brain. Ann Neurol. 2001 Oct;50(4):468–475. doi: 10.1002/ana.1134. [DOI] [PubMed] [Google Scholar]
  7. Castano E. M., Prelli F., Wisniewski T., Golabek A., Kumar R. A., Soto C., Frangione B. Fibrillogenesis in Alzheimer's disease of amyloid beta peptides and apolipoprotein E. Biochem J. 1995 Mar 1;306(Pt 2):599–604. doi: 10.1042/bj3060599. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Citron M., Eckman C. B., Diehl T. S., Corcoran C., Ostaszewski B. L., Xia W., Levesque G., St George Hyslop P., Younkin S. G., Selkoe D. J. Additive effects of PS1 and APP mutations on secretion of the 42-residue amyloid beta-protein. Neurobiol Dis. 1998 Aug;5(2):107–116. doi: 10.1006/nbdi.1998.0183. [DOI] [PubMed] [Google Scholar]
  9. DeMattos R. B., Brendza R. P., Heuser J. E., Kierson M., Cirrito J. R., Fryer J., Sullivan P. M., Fagan A. M., Han X., Holtzman D. M. Purification and characterization of astrocyte-secreted apolipoprotein E and J-containing lipoproteins from wild-type and human apoE transgenic mice. Neurochem Int. 2001 Nov-Dec;39(5-6):415–425. doi: 10.1016/s0197-0186(01)00049-3. [DOI] [PubMed] [Google Scholar]
  10. Dickson D. W. The pathogenesis of senile plaques. J Neuropathol Exp Neurol. 1997 Apr;56(4):321–339. doi: 10.1097/00005072-199704000-00001. [DOI] [PubMed] [Google Scholar]
  11. Dong L. M., Weisgraber K. H. Human apolipoprotein E4 domain interaction. Arginine 61 and glutamic acid 255 interact to direct the preference for very low density lipoproteins. J Biol Chem. 1996 Aug 9;271(32):19053–19057. doi: 10.1074/jbc.271.32.19053. [DOI] [PubMed] [Google Scholar]
  12. Dong L. M., Wilson C., Wardell M. R., Simmons T., Mahley R. W., Weisgraber K. H., Agard D. A. Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. J Biol Chem. 1994 Sep 2;269(35):22358–22365. [PubMed] [Google Scholar]
  13. Drouet B., Fifre A., Pinçon-Raymond M., Vandekerckhove J., Rosseneu M., Guéant J. L., Chambaz J., Pillot T. ApoE protects cortical neurones against neurotoxicity induced by the non-fibrillar C-terminal domain of the amyloid-beta peptide. J Neurochem. 2001 Jan;76(1):117–127. doi: 10.1046/j.1471-4159.2001.00047.x. [DOI] [PubMed] [Google Scholar]
  14. Fagan A. M., Bu G., Sun Y., Daugherty A., Holtzman D. M. Apolipoprotein E-containing high density lipoprotein promotes neurite outgrowth and is a ligand for the low density lipoprotein receptor-related protein. J Biol Chem. 1996 Nov 22;271(47):30121–30125. doi: 10.1074/jbc.271.47.30121. [DOI] [PubMed] [Google Scholar]
  15. Fagan A. M., Holtzman D. M., Munson G., Mathur T., Schneider D., Chang L. K., Getz G. S., Reardon C. A., Lukens J., Shah J. A. Unique lipoproteins secreted by primary astrocytes from wild type, apoE (-/-), and human apoE transgenic mice. J Biol Chem. 1999 Oct 15;274(42):30001–30007. doi: 10.1074/jbc.274.42.30001. [DOI] [PubMed] [Google Scholar]
  16. Fraser P. E., Yang D. S., Yu G., Lévesque L., Nishimura M., Arawaka S., Serpell L. C., Rogaeva E., St George-Hyslop P. Presenilin structure, function and role in Alzheimer disease. Biochim Biophys Acta. 2000 Jul 26;1502(1):1–15. doi: 10.1016/s0925-4439(00)00028-4. [DOI] [PubMed] [Google Scholar]
  17. Golabek A. A., Kida E., Walus M., Perez C., Wisniewski T., Soto C. Sodium dodecyl sulfate-resistant complexes of Alzheimer's amyloid beta-peptide with the N-terminal, receptor binding domain of apolipoprotein E. Biophys J. 2000 Aug;79(2):1008–1015. doi: 10.1016/S0006-3495(00)76354-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Golde T. E., Eckman C. B., Younkin S. G. Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease. Biochim Biophys Acta. 2000 Jul 26;1502(1):172–187. doi: 10.1016/s0925-4439(00)00043-0. [DOI] [PubMed] [Google Scholar]
  19. Guénette S. Y., Tanzi R. E. Progress toward valid transgenic mouse models for Alzheimer's disease. Neurobiol Aging. 1999 Mar-Apr;20(2):201–211. doi: 10.1016/s0197-4580(99)00042-1. [DOI] [PubMed] [Google Scholar]
  20. Han S. H., Einstein G., Weisgraber K. H., Strittmatter W. J., Saunders A. M., Pericak-Vance M., Roses A. D., Schmechel D. E. Apolipoprotein E is localized to the cytoplasm of human cortical neurons: a light and electron microscopic study. J Neuropathol Exp Neurol. 1994 Sep;53(5):535–544. doi: 10.1097/00005072-199409000-00013. [DOI] [PubMed] [Google Scholar]
  21. Holtzman D. M., Bales K. R., Tenkova T., Fagan A. M., Parsadanian M., Sartorius L. J., Mackey B., Olney J., McKeel D., Wozniak D. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2892–2897. doi: 10.1073/pnas.050004797. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Horsburgh K., McCarron M. O., White F., Nicoll J. A. The role of apolipoprotein E in Alzheimer's disease, acute brain injury and cerebrovascular disease: evidence of common mechanisms and utility of animal models. Neurobiol Aging. 2000 Mar-Apr;21(2):245–255. doi: 10.1016/s0197-4580(00)00097-x. [DOI] [PubMed] [Google Scholar]
  23. Janus C., Chishti M. A., Westaway D. Transgenic mouse models of Alzheimer's disease. Biochim Biophys Acta. 2000 Jul 26;1502(1):63–75. doi: 10.1016/s0925-4439(00)00033-8. [DOI] [PubMed] [Google Scholar]
  24. Jordán J., Galindo M. F., Miller R. J., Reardon C. A., Getz G. S., LaDu M. J. Isoform-specific effect of apolipoprotein E on cell survival and beta-amyloid-induced toxicity in rat hippocampal pyramidal neuronal cultures. J Neurosci. 1998 Jan 1;18(1):195–204. doi: 10.1523/JNEUROSCI.18-01-00195.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. LaDu M. J., Falduto M. T., Manelli A. M., Reardon C. A., Getz G. S., Frail D. E. Isoform-specific binding of apolipoprotein E to beta-amyloid. J Biol Chem. 1994 Sep 23;269(38):23403–23406. [PubMed] [Google Scholar]
  26. LaDu M. J., Gilligan S. M., Lukens J. R., Cabana V. G., Reardon C. A., Van Eldik L. J., Holtzman D. M. Nascent astrocyte particles differ from lipoproteins in CSF. J Neurochem. 1998 May;70(5):2070–2081. doi: 10.1046/j.1471-4159.1998.70052070.x. [DOI] [PubMed] [Google Scholar]
  27. LaDu M. J., Lukens J. R., Reardon C. A., Getz G. S. Association of human, rat, and rabbit apolipoprotein E with beta-amyloid. J Neurosci Res. 1997 Jul 1;49(1):9–18. [PubMed] [Google Scholar]
  28. LaDu M. J., Pederson T. M., Frail D. E., Reardon C. A., Getz G. S., Falduto M. T. Purification of apolipoprotein E attenuates isoform-specific binding to beta-amyloid. J Biol Chem. 1995 Apr 21;270(16):9039–9042. doi: 10.1074/jbc.270.16.9039. [DOI] [PubMed] [Google Scholar]
  29. Ladu M. J., Reardon C., Van Eldik L., Fagan A. M., Bu G., Holtzman D., Getz G. S. Lipoproteins in the central nervous system. Ann N Y Acad Sci. 2000 Apr;903:167–175. doi: 10.1111/j.1749-6632.2000.tb06365.x. [DOI] [PubMed] [Google Scholar]
  30. Lins L., Thomas-Soumarmon A., Pillot T., Vandekerchkhove J., Rosseneu M., Brasseur R. Molecular determinants of the interaction between the C-terminal domain of Alzheimer's beta-amyloid peptide and apolipoprotein E alpha-helices. J Neurochem. 1999 Aug;73(2):758–769. doi: 10.1046/j.1471-4159.1999.0730758.x. [DOI] [PubMed] [Google Scholar]
  31. Lund-Katz S., Zaiou M., Wehrli S., Dhanasekaran P., Baldwin F., Weisgraber K. H., Phillips M. C. Effects of lipid interaction on the lysine microenvironments in apolipoprotein E. J Biol Chem. 2000 Nov 3;275(44):34459–34464. doi: 10.1074/jbc.M005265200. [DOI] [PubMed] [Google Scholar]
  32. Ma J., Yee A., Brewer H. B., Jr, Das S., Potter H. Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature. 1994 Nov 3;372(6501):92–94. doi: 10.1038/372092a0. [DOI] [PubMed] [Google Scholar]
  33. Miyata M., Smith J. D. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet. 1996 Sep;14(1):55–61. doi: 10.1038/ng0996-55. [DOI] [PubMed] [Google Scholar]
  34. Morishima-Kawashima M., Oshima N., Ogata H., Yamaguchi H., Yoshimura M., Sugihara S., Ihara Y. Effect of apolipoprotein E allele epsilon4 on the initial phase of amyloid beta-protein accumulation in the human brain. Am J Pathol. 2000 Dec;157(6):2093–2099. doi: 10.1016/s0002-9440(10)64847-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Saunders A. M., Strittmatter W. J., Schmechel D., George-Hyslop P. H., Pericak-Vance M. A., Joo S. H., Rosi B. L., Gusella J. F., Crapper-MacLachlan D. R., Alberts M. J. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 1993 Aug;43(8):1467–1472. doi: 10.1212/wnl.43.8.1467. [DOI] [PubMed] [Google Scholar]
  36. Schmechel D. E., Saunders A. M., Strittmatter W. J., Crain B. J., Hulette C. M., Joo S. H., Pericak-Vance M. A., Goldgaber D., Roses A. D. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A. 1993 Oct 15;90(20):9649–9653. doi: 10.1073/pnas.90.20.9649. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Selkoe D. J. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001 Apr;81(2):741–766. doi: 10.1152/physrev.2001.81.2.741. [DOI] [PubMed] [Google Scholar]
  38. Sheng H., Laskowitz D. T., Bennett E., Schmechel D. E., Bart R. D., Saunders A. M., Pearlstein R. D., Roses A. D., Warner D. S. Apolipoprotein E isoform-specific differences in outcome from focal ischemia in transgenic mice. J Cereb Blood Flow Metab. 1998 Apr;18(4):361–366. doi: 10.1097/00004647-199804000-00003. [DOI] [PubMed] [Google Scholar]
  39. Steinmetz A., Jakobs C., Motzny S., Kaffarnik H. Differential distribution of apolipoprotein E isoforms in human plasma lipoproteins. Arteriosclerosis. 1989 May-Jun;9(3):405–411. doi: 10.1161/01.atv.9.3.405. [DOI] [PubMed] [Google Scholar]
  40. Strittmatter W. J., Weisgraber K. H., Huang D. Y., Dong L. M., Salvesen G. S., Pericak-Vance M., Schmechel D., Saunders A. M., Goldgaber D., Roses A. D. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci U S A. 1993 Sep 1;90(17):8098–8102. doi: 10.1073/pnas.90.17.8098. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Sun Y., Wu S., Bu G., Onifade M. K., Patel S. N., LaDu M. J., Fagan A. M., Holtzman D. M. Glial fibrillary acidic protein-apolipoprotein E (apoE) transgenic mice: astrocyte-specific expression and differing biological effects of astrocyte-secreted apoE3 and apoE4 lipoproteins. J Neurosci. 1998 May 1;18(9):3261–3272. doi: 10.1523/JNEUROSCI.18-09-03261.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Tokuda T., Calero M., Matsubara E., Vidal R., Kumar A., Permanne B., Zlokovic B., Smith J. D., Ladu M. J., Rostagno A. Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid beta peptides. Biochem J. 2000 Jun 1;348(Pt 2):359–365. [PMC free article] [PubMed] [Google Scholar]
  43. Weisgraber K. H. Apolipoprotein E distribution among human plasma lipoproteins: role of the cysteine-arginine interchange at residue 112. J Lipid Res. 1990 Aug;31(8):1503–1511. [PubMed] [Google Scholar]
  44. Weisgraber K. H. Apolipoprotein E: structure-function relationships. Adv Protein Chem. 1994;45:249–302. doi: 10.1016/s0065-3233(08)60642-7. [DOI] [PubMed] [Google Scholar]
  45. Wetterau J. R., Aggerbeck L. P., Rall S. C., Jr, Weisgraber K. H. Human apolipoprotein E3 in aqueous solution. I. Evidence for two structural domains. J Biol Chem. 1988 May 5;263(13):6240–6248. [PubMed] [Google Scholar]
  46. Zhou Z., Smith J. D., Greengard P., Gandy S. Alzheimer amyloid-beta peptide forms denaturant-resistant complex with type epsilon 3 but not type epsilon 4 isoform of native apolipoprotein E. Mol Med. 1996 Mar;2(2):175–180. [PMC free article] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES